AMENDED AND RESTATED NANO-REFORMULATED COMPOUND LICENSE AND OPTION AGREEMENTNano-Reformulated Compound License and Option Agreement • July 11th, 2013 • Iroko Pharmaceuticals Inc. • Pharmaceutical preparations • Delaware
This is a Nano-Reformulated Compound License and Option Agreement, dated June 19, 2007 (the “Effective Date”), and amended and restated as of May 6, 2008 and further amended on October 22, 2008 and December 12, 2012 and amended and restated on December 28, 2012, by and among iCeutica Inc. (“iCeutica Inc.”), a Delaware corporation having an address of One Kew Place, 150 Rouse Boulevard, Philadelphia, PA, 19112, its wholly-owned subsidiary iCeutica Pty Ltd (“iCeutica”) (ACN 113 244 152), an Australian corporation having an address of Unit 4, 97 Hector Street, Osborne Park, Western Australia 6016, and Iroko Pharmaceuticals, LLC (“Iroko”), a Delaware limited liability company having an address of One Kew Place, 150 Rouse Boulevard, Philadelphia, PA, 19112.
